Low-dose alemtuzumab has shown a favourable toxicity profile coupled with good results in terms of efficacy in relapsed/refractory chronic lymphocytic leukaemia (CLL). We conducted a multicentre retrospective study on the routine clinical use of low-dose alemtuzumab in this patient setting. One hundred and eight relapsed/refractory CLL patients from 11 Italian centres were included in the analysis. All patients had an Eastern Cooperative Oncology Group performance status ≤2 and the majority (84%) had adenopathies <5cm. Low-dose alemtuzumab was defined as a total weekly dose ≤45mg and a cumulative dose ≤600mg given for up to 18weeks. The overall response rate was 56% (22% complete remissions). After a median follow-up of 42·2months, the median overall survival and progression-free survival were 39·0 and 19·4months, respectively. In univariate analysis, response was inversely associated with lymph node (P=0·01) and spleen (P=0·02) size, fludarabine-refractoriness (P=0·01) and del(11q) (P=0·009). Advanced age and del(17p) were not associated with a worse outcome. Cumulative dose of alemtuzumab was not associated to response. Toxicities were usually mild and manageable; severe infections occurred in seven patients (7%) during therapy. This retrospective analysis confirms that low-dose alemtuzumab is a valid and currently used therapeutic option for the treatment of relapsed/refractory CLL. © 2011 Blackwell Publishing Ltd.
An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients
CUNEO, Antonio;
2012
Abstract
Low-dose alemtuzumab has shown a favourable toxicity profile coupled with good results in terms of efficacy in relapsed/refractory chronic lymphocytic leukaemia (CLL). We conducted a multicentre retrospective study on the routine clinical use of low-dose alemtuzumab in this patient setting. One hundred and eight relapsed/refractory CLL patients from 11 Italian centres were included in the analysis. All patients had an Eastern Cooperative Oncology Group performance status ≤2 and the majority (84%) had adenopathies <5cm. Low-dose alemtuzumab was defined as a total weekly dose ≤45mg and a cumulative dose ≤600mg given for up to 18weeks. The overall response rate was 56% (22% complete remissions). After a median follow-up of 42·2months, the median overall survival and progression-free survival were 39·0 and 19·4months, respectively. In univariate analysis, response was inversely associated with lymph node (P=0·01) and spleen (P=0·02) size, fludarabine-refractoriness (P=0·01) and del(11q) (P=0·009). Advanced age and del(17p) were not associated with a worse outcome. Cumulative dose of alemtuzumab was not associated to response. Toxicities were usually mild and manageable; severe infections occurred in seven patients (7%) during therapy. This retrospective analysis confirms that low-dose alemtuzumab is a valid and currently used therapeutic option for the treatment of relapsed/refractory CLL. © 2011 Blackwell Publishing Ltd.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
